Inclusion Criteria:

- Male or female, 18 years of age or older.

- Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas.

- May have received prior immunotherapy (including monoclonal antibodies) or vaccine
therapies.

- Measurable disease, according to RECIST criteria.

- Negative pregnancy test (women of childbearing potential only).

- Pretreatment laboratory levels that meet specific criteria.

Exclusion Criteria:

- Prior treatment with Volociximab (M200) or inhibitors of α5β1 integrin (antibodies or
small molecules) or gemcitabine and other chemotherapeutic regimens.

- Known hypersensitivity to murine proteins or chimeric antibodies or other components
of the product.

- Use of any investigational drug within 4 weeks prior to screening or 5 half-lives of
the prior investigational drug (whichever is longer).

- Monoclonal antibody therapy within 4 weeks of the first dose of Volociximab.

- Central Nervous System (CNS) tumor or metastasis.

- History of bleeding disorders within the past year.

- Medical conditions that may be exacerbated by bleeding.